...TLR2) and TLR4 antagonist that inhibits production of proinflammatory cytokines IL-12 and IL-23. VBL granted NanoCarrier Co. Ltd....
...exclusive rights to develop and commercialize VB-111 in Japan (see BioCentury, Nov. 10, 2017 ). NanoCarrier Co. Ltd....

...of Sept. 30, 2017, and received $15 million up front from its November deal with NanoCarrier Co. Ltd....

...wk chg Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) € 42.28 63% Atara Biotherapeutics Inc. (NASDAQ:ATRA) $28.25 53% NanoCarrier Co. Ltd....

...modified murine pre-proendothelin promoter (PPE-1-3x) developed using Vascular Targeting System (VTS) technology. Vascular Biogenics granted NanoCarrier Co. Ltd....
...obadenovec in Japan (see BioCentury, Nov. 10, 2017 ). Vascular Biogenics Ltd. (NASDAQ:VBLT), Modiin, Israel NanoCarrier Co. Ltd....
...and patient reported outcome measures Status: Phase III started Milestone: Phase III data (1Q18) Chris Lieu ofranergene obadenovec VB-111 NanoCarrier Co. Ltd. Vascular...

...Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111...
...inquiries. Vascular Biogenics Ltd. (NASDAQ:VBLT), Modiin, Israel NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Business: Cancer Jaime De Leon ofranergene obadenovec VB-111 VB-201 NanoCarrier Co. Ltd. Toll-like...

...Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111...
...17, 2015) . NanoCarrier gained Y18 to Y742 in Japan on Monday. Jaime De Leon cisplatin micelles Nanoplatin NC-6004 ofranergene obadenovec VB-111 VB-201 NanoCarrier Co. Ltd. Toll-like...

...to inquiries. TPG Biologics Inc. , Taipei, Taiwan NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Business: Drug delivery Alicia Parker NanoCarrier Co. Ltd. TPG...

...the contract had passed," but did not disclose when or whether that period has ended. NanoCarrier Co. Ltd....
...II dose, tumor response and pharmacokinetics Status: Phase I data Milestone: NA Julian Zhu Epirubicin Micelle K-912 NC-6300 Kowa Co. Ltd. NanoCarrier Co. Ltd....

...deal to focus on development in the U.S. and Europe (see BioCentury, Oct. 10, 2011). NanoCarrier Co. Ltd....

...M402) after it fails in a Phase I/II trial to treat advanced metastatic pancreatic cancer NanoCarrier Co. Ltd....